diagnost tool
deliv strong multi-prong growth
driver ahead reiter buy pt
reiter buy rais pt follow volum beat
vs expect initi volum guid ahead expect
driven continu execut industry-lead panorama nipt test also
make impress progress sign deal advanc industry-lead oncolog
liquid biopsi assay ruo expand breadth cancer offer
pharma final activ dialogu aet average-risk nipt
expans readi launch kidney-reject clinic cancer liquid biopsi
test despit big run stock remain lot like buy
volum beat stand volum y/i q/q beat
y/i panorama test y/i q/q beat help
new twin pregnanc readout vistara drove new order mfm
horizon volum y/i q/q beat
solid volum guid initi volum guid y/i prior
estim reiter revenue guid y/i vs
prior/street revenue guid includ new sourc cord
blood signatera oncolog vistara mileston payment
reiter sg
view ntra guid encourag sign new product gain traction
revenu close track volum believ could hit high end
revenue guid updat acog average-risk nipt
result rev y/i line
street panorama nipt rev y/i light
horizon carrier screen rev y/i top gm
came cogs/test slightli
report lp vs hold
cash balanc sheet includ net proce juli rais
pharma deal keep roll studi pharma includ
pharma lead io compani across cancer state
includ lung breast colon prostat pan-canc applic among other
expect mani deal come much higher econom
acog shift would mark upsid estim indic juli nipt
volum average-risk nipt increas june view encourag
sinc acog retir bulletin cast doubt average-risk nipt
expect new acog bulletin one think like move aet issu
formal coverag decis average-risk nipt earli year activ
engag aet continu think coverag polici decis
inevit recent obtain posit coverag decis average-risk nipt
bcb tn live view sign come
model rais volum estim slightli rais revenu estim
updat share count compani recent success secondari offer
rais see page
market leader non-invas blood-
base prenat test enter larg liquid
biopsi cancer organ transplant test market
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
offer price result gross proce million net
proce forma cash balanc stand
model rais revenu estim rais
revenue estim rais revenu estim
rais volum growth project
model gm updat share count model reflect
secondari offer increas revenu estim new share count
along adjust sale multipl discount rate price target move
organ transplant market mark opportun plan enter blood-
base kidney transplant reject test market sometim suspect
possibl time think like expand offer test
organ like heart lung liver peg demonstr
sensit ahead first-to-market lab sensit think
market obvious larg enough least two good player note
model organ transplant revenu model
acknowledg conserv assumpt particularli beyond
acog appear shift posit average-risk nipt earli juli
american colleg obstetrician gynecologist acog withdrew practic bulletin
cast doubt util nipt average-risk women
left acog practic bulletin support see new
bulletin month fall someth expect base
convers one lead nipt compani think larg commerci
payor aet like follow acog endors issu posit coverag
decis average-risk nipt major catalyst howev precis time
clear us present model posit endors acog
coverag aet average-risk birth thu posit develop would
addit estim particularli beyond
target launch multipl uniqu liquid biopsi test custom
patient tumor biolog patient stratif earli detect cancer
recurr compani world awar build liquid
biopsi test custom cancer patient cost good
intend present data breast cancer studi lead
breast cancer summit later year expect san antonio breast cancer
symposium though believ possibl data releas sooner
signatera ruo liquid biopsi test exhibit outstand data relat
recurr monitor lung bladder colon cancer averag lead time
three tumor type come month mean cancer recurr
detect month sooner gold standard signatera deliv
posit predict valu identifi cancer relaps within month
lung bladder colon cancer confid breast cancer data
compar first three target tumor type intend initi target
low hang fruit oncolog offer form ldt though compani
expect pursu fda approv futur believ like launch
initi oncolog assay along kidney transplant reject assay perhap
mid-year
fetal fraction nipt biomark test earlier month announc new studi
result demonstr fetal fraction proport fetal dna mother
blood use independ biomark screen certain chromosom
abnorm advers pregnanc outcom intend launch fetal
fraction biomark offer quarter indic bill order
separ use improv valu care differenti nipt
offer competitor
newer product evercord vistara indic earli roll-out
evercord vistara in-lin expect recal vistara new test
screen cardiac neurolog skelet condit incid
greater syndrom time test requir blood
patient present unabl order one requisit form patient
buy unchang target price august
diagnost tool
panorama optim vistara requir less blood avail one
requisit form expect broader roll-out natera indic vistara
along zygos test detect twin drive adopt maternal-fet medicin
center elsewher manag indic new evercord cord blood bank
servic track line expect recal evercord compet
viacord cord blood registri market estim
annual also think addit new product roadmap
think could includ wg we babi pre-term birth test possibl
smart trial complet enrol first patient august
hope finish mine data look enrol patient
total time public first patient could push
net net view final public smart trial meaning acceler
abil get paid microdelet test dedic
code reimburs complet think could add meaning upsid
realist estim
collabor take time think groundwork place
gradual increas global expans recal natera announc march
agreement develop commerci novel assay content
use generead sequenc believ deal help
scale global across qgen grow still small instal base generead
time decentr test allow custom run sampl local site
sequenc vs send sampl ntra lab process integr solut
allow user access ntra cloud-bas constel softwar remain earli
commerci roll-out model conserv assum zero revenu relat
qiagen nipt test year
rate agre pay up-front licens fee prepaid royalti
option earn addit mileston payment
well on-going royalti payment relat qgen-rel revenu cours
deal size royalti payment disclos howev think
could either match exceed initi cours deal
exchang add industry-lead nipt assay content market leader
could help drive generead placement hospit lab world-wide
expect drive y/i nipt
nice addit oncolog menu view expect add
panorama nipt horizon carrier screen time add proprietari
liquid biopsi test cancer signatera suit
assay readi timet assay develop
generead yet known howev expect assay
immedi avail best guess initi assay launch
generead sometim
deal implic indic
agreement way alter exist suppli agreement ngs-leader
nasdaq buy intend keep use sequenc
lab particularli given strong test accuraci reliabl said ceo
matt rabinowitz indic use best sequenc technolog
lowest cost commit achiev profit expect use
technolog enabl compani get fastest achiev
highest level reliabl test accuraci
buy unchang target price august
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
buy unchang target price august
diagnost tool
